Fluvoxamine for outpatients with COVID-19: where do we stand?-Reference-Cited by-同舟云学术

Fluvoxamine for outpatients with COVID-19: where do we stand?

Published:2022-01 Issue:1 Volume:10 Page:e2-e3
ISSN:2214-109X
Container-title:The Lancet Global Health
language:en
Short-container-title:The Lancet Global Health

Author:

Berwanger Otavio

Publisher

Elsevier BV

Subject

General Medicine

Reference8 articles.

1. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape;Tregoning;Nat Rev Immunol,2021

2. Six months of COVID vaccines: what 1.7 billion doses have taught scientists;Ledford;Nature,2021

3. Fluvoxamine inhibits some inflammatory genes expression in LPS/stimulated human endothelial cells, U937 macrophages, and carrageenan-induced paw edema in rat;Rafiee;Iran J Basic Med Sci,2016

4. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19;Seftel;Open Forum Infect Dis,2021

5. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial;Lenze;JAMA,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brazilian guidelines for the treatment of outpatients with suspected or confirmed COVID-19. A joint guideline of the Brazilian Association of Emergency Medicine (ABRAMEDE), Brazilian Medical Association (AMB), Brazilian Society of Angiology and Vascular Surgery (SBACV), Brazilian Society of Geriatrics and Gerontology (SBGG), Brazilian Society of Infectious Diseases (SBI), Brazilian Society of Family and Community Medicine (SBFMC), and Brazilian Thoracic Society (SBPT);The Brazilian Journal of Infectious Diseases;2022-03

2. Repurposing psychopharmacology: A two-way street?;Journal of Psychopharmacology;2021-12